Liraglutide, a human GLP-1 analogue, lowers HbA(1c) independent of weight loss

Samankaltaisia teoksia

• Liraglutide Is Associated with Reduced Rates of Hypoglycemic Events Versus Glimepiride When Achieving Target HbA(1c)
  Tekijä: Gough, S, et al.
  Julkaistu: (2010)
• Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme.
  Tekijä: Zinman, B, et al.
  Julkaistu: (2012)
• Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: A meta-analysis of the liraglutide clinical trial programme
  Tekijä: Zinman, B, et al.
  Julkaistu: (2012)
• Liraglutide, a human GLP-1 analogue, significantly improves beta cell function in subjects with type 2 diabetes
  Tekijä: Matthews, DR, et al.
  Julkaistu: (2008)
• The imaging of insulinomas using a radionuclide-labelled molecule of the GLP-1 analogue liraglutide: a new application of liraglutide.
  Tekijä: Jing Lv, et al.
  Julkaistu: (2014-01-01)